Researchers at the RIKEN Center for Developmental Biology will treat the first patient in its clinical trial testing an induced pluripotent stem cell-based treatment for age-related macular degeneration.
National Institutes of Health awards contract for CRISPR-based disease modeling in iPS cell lines associated with Alzheimer’s, Stem cell pioneer Bill Skarnes joins advisory board
Clive Svendsen, Meritxell Huch, Ameen Salahudeen, and Maksim Plikus will discuss the latest advances in using patient-derived stem cells to create more accurate disease models.
The Scientist Marketing Team | Sep 26, 2013 | 3 min read
The Scientist brings together a panel of experts who parse the hope and hype in an effort to educate the audience about the successes and caveats of using iPSCs.
Since their discovery in 2006, induced pluripotent stem cells have been poised to reprogram regenerative medicine. Twelve years on, here’s how far they’ve come.